엘레돈 파마슈티컬스, Inc.
DE ˙ DB ˙ US28617K1016
€2.92 ↓ -0.04 (-1.35%)
2026-06-04
주가
SecurityDE:2TK / Eledon Pharmaceuticals, Inc.
InstitutionBnp Paribas Arbitrage, Sa
Latest Disclosed Ownership16,053 shares
Latest Disclosed Value $ 49,443
Bnp Paribas Arbitrage, Sa reports 35.09% increase in ownership of 2TK / Eledon Pharmaceuticals, Inc.

On May 12, 2026 - Bnp Paribas Arbitrage, Sa filed a 13F-HR form disclosing ownership of 16,053 shares of Eledon Pharmaceuticals, Inc. (DE:2TK) valued at $36,922 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 11,883 shares of Eledon Pharmaceuticals, Inc.. This represents a change in shares of 35.09% during the quarter. The current value of the position is $46,875 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F Eledon Pharmaceuticals Equity 28617K101 16,053 4,170 35.09 49 188.24 0.0000
2026-02-10 2025-12-31 13F Eledon Pharmaceuticals Equity 28617K101 11,883 -271 -2.23 18 -45.16 0.0000
2025-11-13 2025-09-30 13F Eledon Pharmaceuticals Equity 28617K101 12,154 7,166 143.66 31 138.46 0.0000
2025-08-14 2025-06-30 13F Eledon Pharmaceuticals Equity 28617K101 4,988 4,988 14 0.0000
2017-05-03 2017-03-31 13F TOKAI PHARMACEUTICALS STOCK 88907J107 0 -378 -100.00 0 -100.00 0.0000
2017-02-14 2016-12-31 13F TOKAI PHARMACEUTICALS STOCK 88907J107 378 -301 -44.33 0 -100.00 0.0000
2016-10-05 2016-09-30 13F * TOKAI PHARMACEUTICALS INC COM STOCK 88907J107 679 282 71.03 1 -50.00 0.0000
2016-07-06 2016-06-30 13F * TOKAI PHARMACEUTICALS INC COM STOCK 88907J107 397 397 2 0.0000
2016-04-22 2016-03-31 13F TOKAI PHARMACEUTICALS INC COM STOCK 88907J107 0 -1,279 -100.00 0 -100.00
2016-04-19 2015-12-31 13F/A-1 TOKAI PHARMACEUTICALS INC COM STOCK 88907J107 1,279 -855 -40.07 11 -50.00 0.0001
2016-02-10 2015-12-31 13F TOKAI PHARMACEUTICALS INC COM STOCK 88907J107 1,279 11
2015-11-13 2015-09-30 13F TOKAI PHARMACEUTICALS INC COM STOCK 88907J107 2,134 1,345 170.47 22 120.00 0.0001
2015-08-14 2015-06-30 13F TOKAI PHARMACEUTICALS INC COM STOCK 88907J107 789 646 451.75 10 900.00 0.0000
2015-05-15 2015-03-31 13F TOKAI PHARMACEUTICALS INC COM STOCK 88907J107 143 143 2 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.